jss101

Jay S. Schneider, Ph.D.

Contact Dr. Schneider

1020 Locust Street
Jefferson Alumni Hall
Suite 521
Philadelphia, PA 19107

(215) 503-0370

Most Recent Peer-reviewed Publications

  1. Effects of developmental lead exposure on the hippocampal methylome: Influences of sex and timing and level of exposure
  2. Developmental lead exposure and prenatal stress result in sex-specific reprograming of adult stress physiology and epigenetic profiles in brain
  3. The Tyrosine Phosphatase STEP Is Involved in Age-Related Memory Decline
  4. Sex-dependent effects of developmental lead exposure on the brain
  5. Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores
  6. Developmental lead and/or prenatal stress exposures followed by different types of behavioral experience result in the divergence of brain epigenetic profiles in a sex, brain region, and time-dependent manner: Implications for neurotoxicology
  7. Strain specific effects of low level lead exposure on associative learning and memory in rats
  8. Sex- and brain region- specific effects of prenatal stress and lead exposure on permissive and repressive post-translational histone modifications from embryonic development through adulthood
  9. Caffeine, creatine, GRIN2A and Parkinson's disease progression
  10. Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1
  11. Sex-dependent effects of lead and prenatal stress on post-translational histone modifications in frontal cortex and hippocampus in the early postnatal brain
  12. Effects of low level lead exposure on associative learning and memory in the rat: Influences of sex and developmental timing of exposure
  13. Epigenetic mechanisms of adverse neurodevelopment in response to lead exposure and prenatal stress and the combination: The road ahead
  14. Intraventricular sialidase administration enhances GM1 ganglioside expression and is partially neuroprotective in a mouse model of Parkinson's disease
  15. Predictors of functional decline in early Parkinson's Disease: NET-PD LS1 Cohort
  16. Caffeine and progression of Parkinson disease: A deleterious interaction with creatine
  17. Pioglitazone in early Parkinson's disease: A phase 2, multicentre, double-blind, randomised trial
  18. Effects of chronic manganese exposure on attention and working memory in non-human primates
  19. Relationship between motor symptoms, cognition, and demographic characteristics in treated mild/moderate Parkinson's disease
  20. GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding